Physician profile
Louis Coates
NPI 1366540791
$10,186.08
in general payments reported to CMS, 2019-2025
65 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $820 · 2021: $1,748 · 2022: $1,168 · 2023: $1,939 · 2024: $1,527 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,351.96 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,074.73 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $917.63 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $763.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $547.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $402.05 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $395.84 | 2019-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.97 | 2019-2024 | Xifaxan, Cycloset |
| Amgen INC. | $359.29 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $343.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $331.98 | 2022-2025 | Auvelity |
| Pfizer INC. | $267.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.39 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $216.89 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $208.76 | 2023-2025 | Rexulti |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Coates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.